Degradation of leucine zipper-positive isoform of MYPT1 may contribute to development of nitrate tolerance

Cardiovascular Research

Volumn 86, Issue 1, 2010, Pages 151-159

  Dou, Dou ^a,b   Ma, Huijuan ^a   Zheng, Xiaoxu ^a   Ying, Lei ^a   Guo, Yixuan ^a   Yu, Xiaoxing ^a   Gao, Yuansheng ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Myosin light chain phosphatase; PKG; Proteasome

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; LEUCINE ZIPPER PROTEIN; MYOSIN LIGHT CHAIN; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; NITRATE; NITRIC OXIDE DONOR; PP1CDELTA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; ISOMETRICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANIMALS; AORTA; CORONARY VESSELS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG TOLERANCE; LEUCINE ZIPPERS; MALE; MICE; MICE, INBRED C57BL; MYOSIN-LIGHT-CHAIN KINASE; MYOSIN-LIGHT-CHAIN PHOSPHATASE; NITRIC OXIDE; NITROGLYCERIN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SYNTHESIS INHIBITORS; SUS SCROFA; VASODILATION; VASODILATOR AGENTS;

EID: 77949386593     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp376     Document Type: Article

References (52)

1. Qin X, Zheng X, Qi H, Dou D, Raj JU, Gao Y. cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric-oxide-induced relaxation in porcine coronary artery. Eur J Physiol (Pflugers Arch) 2007;454:913-923.
2. Qi H, Zheng X, Qin X, Dou D, Xu H, Gao Y. PKG regulates the basal tension and plays a major role in nitrovasodilator-induced relaxation of porcine coronary veins. Br J Pharmacol 2007;152:1060-1069.
3. Stewart DD. Remarkable tolerance to nitroglycerin. Polyclinic 1888;6:43.
4. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest 2004;113:352-354.
5. Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 2005;105:57-68.
6. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005;97:618-628.
7. Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 2006;16:259-265.
8. Münzel T, Sayegh H, Freeman BA, Tarey MM, Harrision DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying nitrate tolerance and cross tolerance. J Clin Invest 1995;95:187-194.
9. Kollau A, Hofer A, Russwurm M, Koesling D, Keung WM, Schmidt K et al. Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for activation of purified soluble guanylate cyclase through direct formation of nitric oxide. Biochem J 2005;385:769- 777.
10. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci USA 2005;102:12159-12164.
11. Sydow K, Daiber A, Oelze M, Chen Z, August M,Wednt M et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004;113:482-489.
12. Difabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 2003;64:1109-1116.
13. Gold ME, Bush PA, Ignarro LJ. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 1989;164:714-721.
14. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 2000;130:211-218.
15. Molina CR, Andersen JW, Rapoport RM, Waldman S, Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 1987;10:371-378.
16. Romanin C, Kukovetz WR. Tolerance to nitroglycerin is caused by reduced guanylate cyclase activation. J Mol Cell Cardiol 1989;21:41-48.
17. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Durán WN, Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008;103:606- 614.
18. Pagani ED, VanAller GS, O'Connor B, Silver PJ. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol 1993;243:141-147.
19. Kim D, Rybalkin SD, Pi XC, Wang Y, Zhang C, Münzel T et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001;104:2338-2343.
20. MacPherson JD, Gillespie TD, Dunkerley HA, Maurice DH, Bennett BM. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J Pharmacol Exp Ther 2006;317:188-195.
21. Dou D, Zheng X, Qin X, Qi H, Liu L, Raj JU et al. Role of cGMP-dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries. Br J Pharmacol 2008;153:497-507.
22. Mülsch A, Oelze M, Klöss S, Mollnau H, Töpfer A, Smolenski A et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001;103:2188-2194.
23. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002;105:1170-1175.
24. Jaikirshan JK, Katherine MJ, Frank VB, Steven AF. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 2001;276:37250-37257.
25. Hartshorne DJ, Ito M, Erd di F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 1998;19:325-341.
26. Wu X, Haystead TA, Nakamoto RK, Somlyo AV, Somlyo AP. Acceleration of myosin light chain dephosphorylation and relaxation of smooth muscle by telokin. J Biol Chem 1998;273:11362-11369.
27. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I. Science 1999;286:1583-1587.
28. Huang QQ, Fisher SA, Brozovich FV. Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem 2004;279:597-603.
29. Lee E, Hayes DB, Langsetmo K, Sundberg EJ, Tao TC. Interactions between the leucine-zipper motif of cGMP-dependent protein kinase and the C-terminal region of the targeting subunit of myosin light chain phosphatase. J Mol Biol 2007;373:1198-1212.
30. Khatri JJ, Joyce KM, Brozovich FV, Fisher SA. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem 2001;276:37250-37257.
31. Payne MC, Zhang HY, Prosdocimo T, Joyce KM, Koga Y, Ikebe M et al. Myosin phosphatase isoform switching in vascular smooth muscle development. J Mol Cell Cardiol 2006;40:274-282.
32. Zhang H, Fisher SA. Conditioning effect of blood flow on resistance artery smooth muscle myosin phosphatase. Circ Res 2007;100:730- 737.
33. Lu Y, Zhang H, Gokina N, Mandala M, Sato O, Ikebe M et al. Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy. Am J Physiol 2008;294:564-571.
34. Chen FC, Brozovich FV. Gene expression profiles of vascular smooth muscle show differential expression of mitogen-activated protein kinase pathways during captopril therapy of heart failure. J Vasc Res 2008;45:445-454.
35. Payne MC, Zhang HY, Shirasawa Y, Koga Y, Ikebe M, Benoit JN et al. Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. Am J Physiol 2004;286:1801-1810.
36. Karim SM, Rhee AY, Given AM, Faulx MD, Hoit BD, Brozovich FV. Vascular reactivity in heart failure: role of myosin light chain phosphatase. Circ Res 2004;95:612-618.
37. Chen FC, Ogut O, Rhee AY, Hoit BD, Brozovich FV. Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardiol 2006;41:488-495.
38. Ararat E, Brozovich FV. Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression. PLoS ONE 2009;4:5144.
39. Wang EQ, Lee WI, Fung HL. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br J Pharmacol 2002;135:299-302.
40. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol 1995;25:674-678.
41. Gerlach H, Pappert D, Lewandowski K, Rossaint R, Falke KJ. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 1993;19:443-449.
42. Meyer RBJ, Miller JP. Analogs of cyclic AMP and cyclic GMP: general methods of synthesis and the relationship of structure to enzymic activity. Life Sci 1974;14:1019-1040.
43. Butt E, Pohler D, Genieser HG, Huggins JP, Bucher B. Inhibition of cyclic GMP dependent protein kinase mediated effects by (Rp) 8 bromo PET cyclic GMPS. Br J Pharmacol 1995;116:3110-3116.
44. Obrig TG, Culp WJ, McKeehan WL, Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 1971;246:174-181.
45. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998;8:397-403.
46. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731.
47. Hashimoto S, Kobayashi A. Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites. Clin Pharmacokinet 2003;42:205-221.
48. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowits PJ et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
49. Francis SH, Corbin JD. Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol 1994;56:237-272.
50. Lincoln TM, Dey N, Sellak H. cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001;91:1421-1430.
51. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006;86:1-23.
52. Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 2004;18:272-279.